As of 2025-12-26, the EV/EBITDA ratio of Lineage Cell Therapeutics Inc (LCTX) is -11.92. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LCTX's latest enterprise value is 344.78 mil USD. LCTX's TTM EBITDA according to its financial statements is -28.92 mil USD. Dividing these 2 quantities gives us the above LCTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2025-12-23 | -11.76 |
| 2025-12-22 | -12.32 |
| 2025-12-19 | -11.92 |
| 2025-12-18 | -12.48 |
| 2025-12-17 | -12.64 |
| 2025-12-16 | -12.88 |
| 2025-12-15 | -12.24 |
| 2025-12-12 | -11.76 |
| 2025-12-11 | -12.16 |
| 2025-12-10 | -12.40 |
| 2025-12-09 | -12.40 |
| 2025-12-08 | -12.00 |
| 2025-12-05 | -12.24 |
| 2025-12-04 | -12.40 |
| 2025-12-03 | -11.92 |
| 2025-12-02 | -11.36 |
| 2025-12-01 | -11.76 |
| 2025-11-28 | -12.56 |
| 2025-11-26 | -12.16 |
| 2025-11-25 | -12.40 |
| 2025-11-24 | -12.48 |
| 2025-11-21 | -12.40 |
| 2025-11-20 | -11.84 |
| 2025-11-19 | -12.16 |
| 2025-11-18 | -12.64 |
| 2025-11-17 | -12.40 |
| 2025-11-14 | -13.51 |
| 2025-11-13 | -12.88 |
| 2025-11-12 | -13.91 |
| 2025-11-11 | -13.04 |
| 2025-11-10 | -12.96 |
| 2025-11-07 | -12.56 |
| 2025-11-06 | -12.32 |
| 2025-11-05 | -13.04 |
| 2025-11-04 | -12.88 |
| 2025-11-03 | -14.15 |
| 2025-10-31 | -13.83 |
| 2025-10-30 | -13.19 |
| 2025-10-29 | -12.16 |
| 2025-10-28 | -12.32 |
| 2025-10-27 | -12.48 |
| 2025-10-24 | -12.08 |
| 2025-10-23 | -11.52 |
| 2025-10-22 | -11.36 |
| 2025-10-21 | -11.68 |
| 2025-10-20 | -11.60 |
| 2025-10-17 | -11.68 |
| 2025-10-16 | -12.08 |
| 2025-10-15 | -12.96 |
| 2025-10-14 | -12.80 |